Piper Jaffray analyst Matt O'Brien said he was not surprised by the news that LivaNova will be shutting down its Caisson Transcatheter Mitral Valve Replacement, or TMVR, program and begin restructuring its heart valve business given the structural and competitive pressures it faces. He believes these are decisions that make sense, as he does not believe there should be a material impact to the top-line but there will be a cost savings benefit, O'Brien tells investors. The analyst, who sees significant value creation coming from the company's evolving treatment-resistant depression, or TRD, franchise, keeps an Overweight rating on LivaNova shares.